Corresponding Author: Jayanth Sridhar, MD, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33136 (jsridhar1@med.miami.edu).
Published Online: July 15, 2021. doi:10.1001/jamaophthalmol.2020.7095
Conflict of Interest Disclosures: Dr Sridhar reported personal fees from Alcon, DORC, Oxurion, and Regeneron Pharmaceuticals. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
1.Isidori
AM , Graziadio
C , Paragliola
RM ,
et al; ABC Study Group. The hypertension of Cushing’s syndrome.
J Hypertens. 2015;33(1):44-60.
PubMedGoogle ScholarCrossref 2.Li
D , El Kawkgi
OM , Henriquez
AF , Bancos
I . Cardiovascular risk and mortality in patients with active and treated hypercortisolism.
Gland Surg. 2020;9(1):43-58.
PubMedGoogle ScholarCrossref 3.Habib
SN , Lin
Z , Puvanachandra
N . Ocular hypertension secondary to high endogenous steroid load in Cushing’s disease.
BMJ Case Rep. 2019;12(1):bcr-2018-226738.
PubMedGoogle Scholar 4.Kersey
JP , Broadway
DC . Corticosteroid-induced glaucoma: a review of the literature.
Eye (Lond). 2006;20(4):407-416.
PubMedGoogle ScholarCrossref 5.Chung
YR , Seo
EJ , Lew
HM , Lee
KH . Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy.
Eye (Lond). 2013;27(12):1339-1346.
PubMedGoogle ScholarCrossref 6.Ji
S , Wei
Y , Chen
J , Tang
S . Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy.
Int J Clin Pharm. 2017;39(3):514-521.
PubMedGoogle ScholarCrossref 7.Lotery
A , Sivaprasad
S , O’Connell
A ,
et al; VICI trial investigators. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI).
Lancet. 2020;395(10220):294-303.
PubMedGoogle ScholarCrossref 8.Schwartz
R , Habot-Wilner
Z , Martinez
MR ,
et al. Eplerenone for chronic central serous chorioretinopathy.
Acta Ophthalmol. 2017;95(7):e610-e618.
PubMedGoogle ScholarCrossref 9.Carvalho-Recchia
CA , Yannuzzi
LA , Negrão
S ,
et al. Corticosteroids and central serous chorioretinopathy.
Ophthalmology. 2002;109(10):1834-1837.
PubMedGoogle ScholarCrossref 10.Bouzas
EA , Scott
MH , Mastorakos
G , Chrousos
GP , Kaiser-Kupfer
MI . Central serous chorioretinopathy in endogenous hypercortisolism.
Arch Ophthalmol. 1993;111(9):1229-1233.
PubMedGoogle ScholarCrossref